Rivaroxaban
Xarelto (rivaroxaban) is a small molecule pharmaceutical. Rivaroxaban was first approved as Xarelto on 2008-09-30. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat acute coronary syndrome, atrial fibrillation, coronary artery disease, peripheral arterial disease, and pulmonary embolism amongst others. The pharmaceutical is active against coagulation factor X. Xarelto's patents are valid until 2039-01-31 (FDA).
| Trade Name | Xarelto |
|---|---|
| Common Name | Rivaroxaban |
| ChEMBL ID | CHEMBL198362 |
| Indication | acute coronary syndrome, atrial fibrillation, coronary artery disease, peripheral arterial disease, pulmonary embolism, replacement arthroplasty, stroke, venous thromboembolism, venous thrombosis |
| Drug Class | Antithrombotic: blood coagulation factor XA inhibitors |
